

Examining the Molecular Basis of Type 1 Diabetes

Bianca Flaim, Oluwalonimi Ayekun, and Alexander Turco

October 28, 2022

¹ Department of Biology, McMaster University, Hamilton, ON, Canada

Literature Review

What is Type 1 Diabetes

Over the last 70 years, developed countries around the world have seen a steady increase in the incidence of type 1 diabetes (T1D) (Patterson et al. 2012; Todd 2010). It is generally thought that T1D is due to the immune-mediated destruction of pancreatic β -cells which are responsible for the production of insulin (Atkinson, G S Eisenbarth, and Michels 2014; Todd 2010). Autoantibodies specifically targeting β -cells, as well as macrophage and lymphocyte infiltration of the pancreas are responsible for the destruction of insulin-producing β -cells (Van den Driessche et al. 2009). These β -cells are found within the islets of Langerhans and they have the ability to sense glucose and subsequently release insulin to maintain healthy blood-glucose levels (Bluestone, Herold, and G Eisenbarth 2010). Although it is known to be a common chronic disease in children, diagnosis of T1D can occur at any age (Atkinson, G S Eisenbarth, and Michels 2014). Symptoms associated with disease onset, especially in children and adolescents, are typically polydipsia (extreme thirst), polyphagia (extreme hunger), polyuria (excessive urination), and hyperglycaemia (high blood sugar) (Atkinson, G S Eisenbarth, and Michels 2014). Research surrounding T1D tends to revolve around the search for environmental triggers, as well as genetic factors which contribute to the disease (Todd 2010). Rapid advancements in both molecular biology and genetic sequencing methods have contributed to an increase in papers which examine the genetic basis of the disease. It is believed that the nature component (genetic factors, molecules, cells) of T1D will provide insight into disease mechanisms, and at the same time help researchers to identify environmental factors which play a role in the development of the disease (Todd 2010).

Insulin Hormone Production and Release

The insulin hormone is a peptide hormone encoded on INS gene, found on chromosome 11 (cluster p15.5) (Ohneda, Ee, and German 2000; Tokarz, MacDonald, and Klip 2018). Gene expression is regulated by several enhancer elements found upstream of the INS gene, including IDX1, MafA, NeuroD1 (Tokarz, MacDonald, and Klip 2018). As insulin is a key hormone involved in the feedback loop to establish blood glucose homeostasis, glucose levels also influence insulin production (Ohneda, Ee, and German 2000; Vranic, Hollenberg, and Steiner 1985). Transcription from the INS gene yields a preproinsulin mRNA molecule, which exits the β -cell's nucleus and is translated by ribosomes situated within the rough endoplasmic reticulum (RER) to produce a preproinsulin polypeptide (Tokarz, MacDonald, and Klip 2018). After translation, a series of posttranslational modifications are required, beginning with removal of the signal sequence within the RER (Tokarz, MacDonald, and Klip 2018). Signal removal allows polypeptide (now proinsulin) trafficking to the trans-Golgi network, where the C-peptide is proteolytically cleaved by the prohormone convertases PC1/3 and PC2 (Klimek et al. 2009; Tokarz, MacDonald, and Klip 2018). Proinsulin is then appropriately folded and stabilized through the formation of disulfide bonds, yielding a mature insulin protein (Mathieu, Gillard, and Benhalima 2017; Tokarz, MacDonald, and Klip 2018). Insulin is then packaged into granules

and trafficked along the cell's actin microtubule network where they are stored within the β -cell's plasma membrane, prepared for secretion once the cell receives the appropriate signal to release insulin (Tokarz, MacDonald, and Klip 2018).

Glucose entry in the β -cell triggers a cascade of intracellular events which terminates in insulin release. Once blood glucose rises typically above 100 mg/dL, glucose begins to enter the β -cell's cytoplasm via membrane GLUT1 channels (Tokarz, MacDonald, and Klip 2018; Vranic, Hollenberg, and Steiner 1985). Glucokinase then phosphorylates the glucose, trapping it within the cell and beginning the process of glycolysis, resulting in the production of adenosine triphosphate (ATP) and pyruvate (Tokarz, MacDonald, and Klip 2018). Pyruvate then undergoes subsequent metabolic steps, including entering the Krebs cycle and the electron transport chain within the mitochondria, resulting in the production of lots of ATP. Within the cytoplasm, the increased ATP/adenosine diphosphate (ADP) ratio is detected, resulting in the closure of ATP-sensitive K⁺ ion channels (Tokarz, MacDonald, and Klip 2018). Since the potassium ions can no longer flow out of the cell, the closure of these channels results in a more positive membrane potential, leading to depolarization of the cell once the membrane potential reaches -50 millivolts (mV) (Tokarz, MacDonald, and Klip 2018). Depolarization of the cell activates voltage-dependent Na⁺ and Ca²⁺ channels, allowing the influx of sodium and calcium ions, further increasing membrane potential (Tokarz, MacDonald, and Klip 2018). The influx of calcium ions triggers SNARE proteins, Munc18, and syntaxin proteins to initiate insulin vesicle fusion and release into the bloodstream (Tokarz, MacDonald, and Klip 2018). As insulin is released and plasma glucose levels begin to drop, the signal is terminated as the SERCA pump removes calcium ions from the β -cell's cytoplasm (Tokarz, MacDonald, and Klip 2018). Additionally, the signal is terminated as granule exocytosis requires ATP hydrolysis, thus reducing the cytosolic ATP:ADP ratio, and triggering the reopening of ATP-sensitive K⁺ channels (Tokarz, MacDonald, and Klip 2018). Allowing potassium ions to flow out of the cell reduces the membrane potential, resulting in the closure of voltage-gated Na⁺ and Ca²⁺ channels. The process of insulin release has been described as a biphasic process, with an initial burst as the cell initially depolarizes and releases all primed insulin granules within the cell membrane, and a second, prolonged phase as the cell's network reorganizes itself to recruit more insulin granules to the plasma membrane for subsequent exocytosis (Tokarz, MacDonald, and Klip 2018). Within an islet of Langerhans, which contains many β -cells, which are connected by gap junctions, allowing rapid paracellular cell-to-cell communication, and resulting in a large, rapid, release of insulin from the pancreas when needed (In't Veld and Marichal 2010; Tokarz, MacDonald, and Klip 2018).

Insulin-Insulin Receptor Binding Mediated Glucose Storage and Uptake

Insulin binds to the insulin receptor (IR) expressed on the cell membrane of its target cells. The IR is a disulphide-linked receptor tyrosine kinase homodimer comprised of two α -subunits and two β -subunits. After insulin binding, the IR undergoes a conformational change bringing the two IR monomers closer and allowing for autophosphorylation (De Meyts 2016). During autophosphorylation, each IR monomer adds a phosphate group to the β -unit of the other IR monomer resulting in the activation of the IR receptor. Once activated, the IR becomes capable of activating and binding to the adaptor protein insulin-receptor substrate 1 (IRS-1). IRS-1 acts as a docking site for proteins with Src-homology-2 domains, such as the p85 subunit of PI

(3)K which helps facilitate the recruitment PI (3)K to the plasma membrane (Lizcano and Alessi 2002; Sun et al. 1991). Upon being recruited to the plasma membrane, PI (3)K catalyzes the conversion of phosphatidylinositol (4,5)-biphosphate (PI (4,5) P2) into phosphatidylinositol (3,4,5) triphosphate (PI (3,4,5) P3). PI (3,4,5) P3 can phosphorylate the AKT (also known as protein kinase B) (Sun et al. 1991). The increased concentration of PI (3,4,5) P3 molecules along the cell membrane facilitates the recruitment of AKT to the plasma membrane. Once at the plasma membrane, AKT is phosphorylated by two other protein kinases, PDK1 at residue Thre308 and MTORC at residue Ser473. The phosphorylation of the protein at these two residues allows for its activation (Leto and Saltiel 2012; Menting et al. 2013). Upon its activation, AKT dissociates from the membrane and begins to interact with number of different effector proteins within the cytosol and nucleus, including GSK3 (Lizcano and Alessi 2002). GSK3 is a serine/threonine protein kinase that can inhibit the activity of glycogen synthase, a key enzyme in the process of glycogenesis. When AKT phosphorylates GSK3 it inhibits the activity of this kinase, therefore increasing glycogen synthase and the rate of glucose-to-glycogen conversion. This is how insulin increases glucose storage inside of muscle and fat cells.

In addition to glucose storage, insulin also helps facilitate the process of GLUT-4 translocation to the cell membrane in muscle and adipose (fat) cells. GLUT-4 is one of the several GLUT proteins responsible for transporting glucose across the blood vessel into cells in the human body (Li et al. 2019). When insulin is not bound to the IR, about 80% of GLUT-4 remains sequestered in specialized, intracellular organelles known as GLUT-4 storage vesicles (GSVs) while the other 20% cycle slowly between the GSVs and plasma membrane (Fazakerley, Koumanov, and Holman 2022). Within 5-10 minutes of insulin-mediated intracellular signalling, the number of GLUT-4 receptors expressed along the surface of adipose and fat cells increases by over 50% (Fazakerley, Koumanov, and Holman 2022; Stöckli, Fazakerley, and James 2011). Insulin increases the amount of GLUT-4 at the plasma membrane primarily by promoting the fusion of GSVs with the plasma membrane (also known as GSVs exocytosis) (Leto and Saltiel 2012). Like with glucose storage, AKT acts as a central mediator of this process through its intracellular interactions with several important molecules and proteins involved in GSVs exocytosis. For instance, AKT is capable of phosphorylating both RAB-GAP AS160 (also referred to asTBC1D4) and the RAL-GAP complex, each of which have important roles in GLUT-4 vesicle trafficking and targeting to the plasma membrane (De Meyts 2016; Leto and Saltiel 2012). Along with RAB-GAP AS160 and the RAL-GAP complex, AKT has also been shown to interact with SNARE regulatory proteins, SYNIP and CDP138, which are necessary for the fusion of GSVs to the plasma membrane.

In addition to the PI (3)K-AKT pathway, however, insulin is also capable of promoting GLUT-4 translocation via another intracellular signalling pathway. This pathway is mediated by the adaptor protein APS, which binds with high affinity to the insulin-receptor (Yu et al. 2007). After APS is phosphorylated by the IR, it recruits a complex consisting of the proto-oncogene c-CBL and the-CBL associated protein (CAP) facilitating the IR-catalyzed Tyr phosphorylation of c-CBL. Following phosphorylation by the IR, c-CBL becomes capable of interacting with the adaptor protein CRK which is bound to the GEF (Guanine-Exchange-Factor) C3G. This interaction allows C3G to initiate the activation of TC10, an RHO-family GTP-Ase, localized in the lipid rafts of the plasma membrane (Leto and Saltiel 2012). TC10 is then able to interact with its' effector

protein called PIST 1, which then binds to and directs the cleavage of the protein TUG. In basal conditions (under low insulin concentration), TUG binds to GLUT-4 in GSVs preventing the trafficking of these GSVs, and thus GLUT-4 translocation, to the plasma membrane. Insulin-induced cleavage of the TUG protein stimulates the dissociation of protein from GLUT-4 enabling the trafficking of GSVs to the plasma membrane (Li et al. 2019; Yu et al. 2007). In the absence of this step, GSVs regulated trafficking and GLUT-4 translocation is inhibited in adipocyte cells (Chang, Chiang, and Saltiel 2004). In addition to facilitating the cleavage of TUG, TC10 also interacts with the protein EXO70 which belongs to the exocyst complex and is involved in the docking of secretory vesicles to the plasma membrane.

Type 1 Diabetes Symptom Pathophysiology and Possible Complications

T1D is said to proceed in 3 phases – two presymptomatic phases, followed by a symptomatic phase that increases in severity as the disease progresses (Katsarou et al. 2017; Norris, Johnson, and Stene 2020). The first phase is characterized by initial immune infiltration of the pancreas by macrophages, dendritic cells, CD8+ and CD4+ T-cells, and autoantibodies specific against β -cells, resulting in the rapid loss of functional β -cells (Katsarou et al. 2017). This stage is followed by the initial development of hyperglycemia, which may present as asymptomatic at first as the pancreas retains some functionality (Katsarou et al. 2017). As immune destruction continues, β -cell functionality dramatically decreases, resulting in more severe hyperglycemia and the development of symptoms (Katsarou et al. 2017). Primary symptoms include polyuria, polydipsia, and polyphagia (R A Guthrie and D W Guthrie 2004). As glucose accumulates within the bloodstream, the kidneys attempt to rectify the imbalance by excreting more glucose in the urine (R A Guthrie and D W Guthrie 2004). As the nephron excretes glucose into the urine, water follows from the bloodstream into the urine, resulting in a greater volume of urine and the primary symptom of polyuria (R A Guthrie and D W Guthrie 2004). Increased urination in attempts to reduce blood glucose results in dehydration, so this causes the polydipsia as the body's mechanism to increase water intake and restore hydration and water homeostasis (R A Guthrie and D W Guthrie 2004). The final primary symptom, polyphagia, is increased hunger due to reduced fuel available to cells (R A Guthrie and D W Guthrie 2004). Primary complications include nephropathy, neuropathy, retinopathy, risk of cardiovascular disease and peripheral artery disease, and risk of cerebrovascular disease (Katsarou et al. 2017; McGill and Levitsky 2016; Melendez-Ramirez, Richards, and Cefalu 2010; Wherrett et al. 2018). These conditions are largely related to the severity and length of hyperglycemic exposure, especially due to the increased stress on the kidneys due to increased glucose excretion. As hyperglycemia exposure increases, this can increase the risk of albuminuria, which may progress to complete nephropathy (Melendez-Ramirez, Richards, and Cefalu 2010). Neuropathy may arise in the case of hypoglycemia (in instances where too much insulin is injected), as the brain primarily relies on glucose as its fuel source, and reduced glucose delivery to the brain may result in neuronal death and possible cognitive impairments and deficits (Katsarou et al. 2017). Hyperglycemia is also linked to the production of microaneurysms in blood vessels feeding the retina, leading to possible retinopathy and fluid leakage resulting in macular edema (Melendez-Ramirez, Richards, and Cefalu 2010). Lastly, hyperglycemia can trigger a severe complication known as diabetic ketoacidosis (DKA). Hyperglycemia causes the production of ketones as an alternate source of fuel when insulin is critically low, and cells cannot access glucose (Cashen and Petersen

2019). In this case, ketogenesis begins, and can result in the acidification of the blood, and can also result in cerebral edema and hypokalemia which can become fatal in severe cases (Cashen and Petersen 2019).

Mutations associated with Type 1 Diabetes

T1D is a complex disease, meaning it can be influenced by a variety of environmental and genetic risk factors (Brorsson et al. 2010). The concordance of T1D among monozygotic and dizygotic twins, as well as numerous studies that have identified genes associated with T1D, provide good evidence for a strong genetic determinant of disease (Erich et al. 2008). For over thirty years, it has been known that the human leukocyte antigen (HLA) region on chromosome 6 contributes to the risk of developing T1D (Brorsson et al. 2010). The HLA region contains genes which code for proteins that have immune function, particularly in the regulation of the immune response (Choo 2007). More specifically, it has been found that certain alleles at the HLA-DRB1, HLA-DQA1, and HLA-DQB1 loci are more strongly associated with T1D than others (Erich et al. 2008). Although studies have identified these specific alleles, the consensus remains that more work must be done to further identify causative variants and their DNA profile (Brorsson et al. 2010). The complexity of T1D makes it extremely difficult to narrow down the cause to one single gene, but there are a very small number of diabetes cases which do in fact result from single gene mutations (Yang and Chan 2016). Two major forms of monogenic diabetes are Neonatal diabetes mellitus (NDM) and maturity-onset diabetes of the young (MODY) (Yang and Chan 2016). These monogenic forms of diabetes are typically the result of mutations in genes which code for proteins that reduce β -cell function (Steck and Winter 2011). It is interesting to note that the single gene mutations found to cause NDM and MODY, have also been found to be associated with T1D (Yang and Chan 2016). Two examples of monogenic diabetes genes which have also been found to be associated with T1D are the preproinsulin gene (*INS*), and the Gli-similar 3 gene (*GLIS3*) (Yang and Chan 2016). The *GLIS3* gene codes for a transcription factor which regulates islet development and insulin gene transcription, and the *INS* gene encodes the peptide hormone insulin (Steck and Winter 2011; Yang and Chan 2016). Single nucleotide polymorphisms (SNPs) are typically what affect the normal function of both genes, but it has also been found that allelic variants of the genes lead to both monogenic diabetes and T1D (Yang and Chan 2016).

Type 1 Diabetes Treatments and Health Considerations

As the β -cell functionality is destroyed due to immune destruction, functionality cannot be restored. Thus, the standard of care involves continuous glucose monitoring and regulation of blood sugar levels via insulin injections (McGill and Levitsky 2016). Many patients opt for insulin pumps, otherwise known as a closed-loop pancreas system (Wherrett et al. 2018). This system is an artificial system that features an insulin pump, and a glucose sensor which can detect when insulin should be secreted. Some of these systems may infuse just insulin, others also feature a glucagon pump to increase blood sugar in case too much insulin was secreted (Wherrett et al. 2018). Alternatively, patients may opt for standard insulin injections. A key component of T1D treatment is patient education on their condition and the body's natural fluctuations of blood sugar levels

throughout the day. For example, it is important for patients to understand that prolonged fasting, illness, or intense exercise can reduce blood sugar levels and naturally cause a hypoglycemic crisis (McGill and Levitsky 2016). In the event of hypoglycemia, it is important to detect as soon as possible and consume a small amount of sugar (15 grams typically recommended, available in juice, candies, or glucose gels) (Katsarou et al. 2017). Lifestyle changes such as eating snacks prior to bedtime and exercising earlier in the day can be beneficial in preventing nocturnal hypoglycemia (McGill and Levitsky 2016). Due to the number of potential complications which may arise from T1D, physicians should also monitor patients for other comorbidities including other autoimmune conditions, kidney failure, dyslipidemia, retinopathy, and other hormonal disease (Katsarou et al. 2017). Further, patients are encouraged to consult dietitians to develop healthy meal plans to regulate blood sugar levels and join community support groups (Katsarou et al. 2017). T1D patients are at increased risk of mental health issues such as anxiety, depression, and eating disorders due to the perceived lack of autonomy and increased stress load due to their disease (Katsarou et al. 2017).

References

Atkinson Mark A, Eisenbarth George S, and Michels Aaron W (2014). Type 1 diabetes. *The Lancet* 383(9911), 69–82.

This source touches on the epidemiology of T1D, as well as the high prevalence of T1D in children. Also mentioned in this paper are the typical symptoms associated with T1D disease onset.

Bluestone Jeffrey A, Herold Kevan, and Eisenbarth George (2010). Genetics, pathogenesis and clinical interventions in type 1 diabetes. *Nature* 464(7293), 1293–1300.

This paper focuses on the pathophysiology of T1D. It does an excellent job explaining the immunologic history of T1D, as well as providing potential targets of immune intervention in T1D.

Brorsson Caroline et al. (2010). The type 1 diabetes-HLA susceptibility interactome-identification of HLA genotype-specific disease genes for type 1 diabetes. *PLoS One* 5(3), e9576.

This source dives into the complexities associated with the human leukocyte antigen region which has been found to contribute to the risk of developing diabetes. The paper describes the role of the HLA region very well.

Cashen Katherine and Petersen Tara (2019). Diabetic ketoacidosis. *Pediatrics in Review* 40(8), 412–420.

This source was useful in understanding the key mechanism underlying diabetic ketoacidosis, one of the most severe and potentially fatal complications associated with prolonged hyperglycemia and chronically low insulin.

Chang Louise, Chiang Shian-Huey, and Saltiel Alan R (2004). Insulin signaling and the regulation of glucose transport. *Molecular medicine* 10(7), 65–71.

This article was necessary for understanding in understanding the multiple stages involved in the GLUT-4 translocation including the interaction between GLUT-4 and the plasma membrane under basal (fasting conditions) in the human body. As well as an overview of processes governing the insulin-mediated APS pathway and PI (3)K pathway in glucose uptake and storage, including the relationship between TC10 and the EXO70 protein complex.

Choo Sung Yoon (2007). The HLA system: genetics, immunology, clinical testing, and clinical implications. *Yonsei medical journal* 48(1), 11–23.

This paper specifically focuses on the genes which make up the HLA region, as well as the role of these genes in healthy individuals.

De Meyts Pierre (2016). The insulin receptor and its signal transduction network. *Endotext* [Internet].

This article was important for understanding the molecular structure of insulin receptor and the mechanisms underlying insulin-insulin receptor binding. The authors also briefly discuss the insulin regulation of GLUT4 translocation, the proteins involved in AKT/PKB activation, and the structure of the insulin hormone.

Erlich Henry et al. (2008). HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. *Diabetes* 57(4), 1084–1092.

This paper goes into detail regarding evidence for a strong genetic determinant of T1D. It also mentions specific alleles at the DRB1, DQA1, and DQB1 loci which tend to be associated with T1D.

Fazakerley Daniel J, Koumanov Francoise, and Holman Geoffrey D (2022). GLUT4 On the move. *Biochemical Journal* 479(3), 445–462.

This article was helping in understanding both the kinetics involved in insulin-mediated GLUT-4 translocation, in addition to the general intracellular mechanisms allowing for this process to occur.

Guthrie Richard A and Guthrie Diana W (2004). Pathophysiology of diabetes mellitus. *Critical care nursing quarterly* 27(2), 113–125.

This source was of great use in writing this report as it detailed the mechanism underlying the key symptoms involved in type 1 diabetes. This source also detailed some of the major complications involved in type 1 diabetes.

In't Veld Peter and Marichal Miriam (2010). Microscopic anatomy of the human islet of Langerhans. *The islets of Langerhans*, 1–19.

This source was useful in understanding the anatomy of the pancreas, especially with regards to the proportions of cells within the islets of Langerhans, and the role of key pancreatic endocrine cells.

Katsarou Anastasia et al. (2017). Type 1 diabetes mellitus. *Nature reviews Disease primers* 3(1), 1–17.

This source was of great use in identifying the autoimmune etiology and specific events associated with the progression of type 1 diabetes. Further, this source also identified some of the key serious complications associated with untreated type 1 diabetes, common comorbidities, and proper insulin management techniques.

Klimek AM et al. (2009). Impaired proinsulin processing is a characteristic of transplanted islets. *American Journal of Transplantation* 9(9), 2119–2125.

The purpose of this source was to explore the key events in the processing pathway of proinsulin within pancreatic beta-cells. The journal article also identified the key catalytic enzymes involved in the posttranslational proteolytic cleavage events involved in the production of mature insulin.

Leto Dara and Saltiel Alan R (2012). Regulation of glucose transport by insulin: traffic control of GLUT4. *Nature reviews Molecular cell biology* 13(6), 383–396.

This article was important for understanding the processes involved in GLUT-4 trafficking regulation and insulin-mediated GLUT-4 exocytosis, but mainly PI (3)K-dependant insulin signalling. It also covers the mechanisms underlying GLUT-4 endocytosis and retention within adipose and muscle cells.

Li Don T et al. (2019). Focus: Organelles: GLUT4 Storage Vesicles: Specialized Organelles for Regulated Trafficking. *The Yale journal of biology and medicine* 92(3), 453.

This article was useful in understanding the role that insulin-signaling plays in GLUT-4 translocation, specifically with an emphasis on the role of the TUG protein in insulin-mediated GLUT-4 translocation.

Lizcano Jose M and Alessi Dario R (2002). The insulin signalling pathway. *Current biology* 12(7), R236–R238.

This article was important for understanding the mechanisms involved in PI(3)K signalling pathway.

Mathieu Chantal, Gillard Pieter, and Benhalima Katrien (2017). Insulin analogues in type 1 diabetes mellitus: getting better all the time. *Nature Reviews Endocrinology* 13(7), 385–399.

This source was especially useful for this review in understanding the important folding events involved in the production of mature insulin and the 3D structure of the protein hormone.

McGill Dayna E and Levitsky Lynne L (2016). Management of hypoglycemia in children and adolescents with type 1 diabetes mellitus. *Current diabetes reports* 16(9), 1–6.

The purpose of this source was to identify some of the blood sugar management techniques and treatments for patients with type 1 diabetes. This source also identified some of the risks of chronic hyperglycemia associated with improper/insufficient type 1 diabetes treatment.

Melendez-Ramirez L Yvonne, Richards Robert J, and Cefalu William T (2010). Complications of type 1 diabetes. *Endocrinology and Metabolism Clinics* 39(3), 625–640.

This source discussed in great detail the mechanisms underlying many of the common severe complications associated with type 1 diabetes and chronic hyperglycemia, such as details leading to the development of type 1 diabetes-related retinopathy.

Menting John G et al. (2013). How insulin engages its primary binding site on the insulin receptor. *Nature* 493(7431), 241–245.

This article provided additional insight into the structure of insulin receptors and the mechanics governing insulin-insulin receptor binding.

Norris Jill M, Johnson Randi K, and Stene Lars C (2020). Type 1 diabetes—Early life origins and changing epidemiology. *The lancet Diabetes & endocrinology* 8(3), 226–238.

This source was particularly useful in identifying the autoimmune destruction of pancreatic beta-islet cells leading to the onset of type 1 diabetes. This source identified the phases of autoimmune destruction (asymptomatic and symptomatic phases), as well as the key immune cells that are involved in the destruction of the beta-cells.

Ohneda Kinuko, Ee Hooi, and German Michael (2000). Regulation of insulin gene transcription. In: *Seminars in cell & developmental biology*. Vol. 11. 4. Elsevier, 227–233.

This source was also useful in elucidating more regarding the gene expression and regulation of the INS gene encoding the insulin protein. This source identified specific gene clusters within chromosome 11 encoding the protein, as well as the preproinsulin mRNA structure with regards to numbers of exons and introns.

Patterson Chris C et al. (2012). Trends in childhood type 1 diabetes incidence in Europe during 1989–2008: evidence of non-uniformity over time in rates of increase. *Diabetologia* 55(8), 2142–2147.

This paper touches on the incidence of T1D, and provides excellent information regarding the notable trends in terms of T1D diagnoses across Europe. The author also emphasizes the predicted increase in the incidence of T1D.

Steck Andrea K and Winter Wiliam E (2011). Review on monogenic diabetes. *Current Opinion in Endocrinology, Diabetes and Obesity* 18(4), 252–258.

Another source which focuses on the forms of monogenic diabetes. This paper mentions in great detail the role of the genes found to cause monogenic diabetes.

Stöckli Jacqueline, Fazakerley Daniel J, and James David E (2011). GLUT4 exocytosis. *Journal of cell science* 124(24), 4147–4159.

This article was useful in providing additional insight into the mechanisms and stages involved in insulin-mediated GLUT-4 exocytosis.

Sun Xiao Jian et al. (1991). Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. *Nature* 352(6330), 73–77.

This paper touches on the complexities regarding the structure of the insulin receptor, and how insulin functions at the cellular level.

Todd John A (2010). Etiology of type 1 diabetes. *Immunity* 32(4), 457–467.

This source provided an excellent overview of the etiology of T1D. It also mentions genetic factors which contribute to T1D including the HLA region, as well as environmental factors which contribute to T1D including sanitation, healthcare, and diet.

Tokarz Victoria L, MacDonald Patrick E, and Klip Amira (2018). The cell biology of systemic insulin function. *Journal of Cell Biology* 217(7), 2273–2289.

The purpose of this source with regards to this report was to identify the important steps involved in the production of insulin within beta-cells. Specifically, this source identified gene expression patterns and regulation, as well as the mechanism regulating insulin release and secretion from beta-cells in periods of high blood sugar.

Van den Driessche A et al. (2009). Type 1 diabetes and autoimmune polyglandular syndrome: a clinical review. *Neth J Med* 67(11), 376–87.

This article focuses on the immunological aspects of T1D. It goes into detail about macrophage and lymphocyte infiltration of the pancreas and how this leads to the reduction in insulin.

Vranic Mladen, Hollenberg Charles H, and Steiner George (1985). *Comparison of Type I and Type II Diabetes: Similarities and Dissimilarities in Etiology, Pathogenesis, and Complications*. Springer.

This source was useful for identifying the factors the influence insulin release by pancreatic beta-cells, as well as specific blood sugar thresholds marking insulin release. Insulin is managed and released via a feedback loop, which is somewhat complicated by the effects of various other biological events, for example other hormones and amino acid levels.

Wherrett Diane K et al. (2018). Type 1 diabetes in children and adolescents. *Canadian journal of diabetes* 42, S234–S246.

The purpose of this source was to discuss some of the major health complications and adverse outcomes associated with improper treatment of type 1 diabetes, as well as common insulin management techniques and treatments.

Yang Yisheng and Chan Lawrence (2016). Monogenic diabetes: what it teaches us on the common forms of type 1 and type 2 diabetes. *Endocrine reviews* 37(3), 190–222.

This paper provides information regarding two forms of monogenic diabetes. More specifically, it focuses on mutations known to cause monogenic diabetes, and how these mutations can also be associated with T1D.

Yu Chenfei et al. (2007). The glucose transporter 4-regulating protein TUG is essential for highly insulin-responsive glucose uptake in 3T3-L1 adipocytes. *Journal of Biological Chemistry* 282(10), 7710–7722.

This article illustrates the necessary role of the TUG protein in insulin-mediated glucose uptake through a series of experiments conducted involved in stable TUG depletion and enhancement.